Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)

Detailed Description
-----------------
the participants will follow up the patient for 1 year in the first visit All patients in this study will be subjected to: Detailed history. Careful physical examination laboratory investigation complete blood picture. liver function kidney function Iron profile(serum iron ,serum ferritin ESR (erythrocyte sedimentation rate ) g-CRP (C reactive protein) f-LDH (lactate dehydrogenase) Abdominal us(the colon wall thickness,lymph nodes,mass,other organs) Doppler us (mesenteric vessels) colonoscopy after 1 year of treatment follow up every 3 months by abdominal US and peripheral hemogram and last visit after 1 year colonoscopy and biopsy for assessment response to treatment

Official Title
-----------------
Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Diseases

Intervention / Treatment
-----------------
* Drug: Infliximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria patients diagnosed ulcerative colitis at age(15-60) patients diagnosed crohns disease at age(15-60)k Exclusion criteria liver cirrhosis and portal hypertension spontaneous bacterial peritonitis Ischemic colitis

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patient on traditional therapy<br>Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet) | Drug: Infliximab<br>* follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy<br>* Other names: steroid,immuran 5ASA;|
| patient on infliximab<br>drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months | Drug: Infliximab<br>* follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy<br>* Other names: steroid,immuran 5ASA;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the role abdominal ultrasound in assessment inflammatory bowel disease | measure the thickness of the colon by abdominal ultrasound and doppler mesenteric vessels .more than 4ml detect activity doppler mesenteric highly vascularity in activity | 2 year |